Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[EX Q]: Paragraph: Depression is one of the most common forms of mental illness, affecting more than 350 million people worldwide. It is ranked by the World Health Organization as the leading cause of disability globally. Treatment usually involves either medication, some form of  psychotherapy or a combination of both. Yet many patients fail to get better and suffer recurring bouts of illness. MBCT was developed to help such people by teaching them skills to recognize and respond constructively to thoughts and feelings associated with relapse, aiming to prevent a downward spiral into depression. In the first large study to compare MBCT and anti-depressants, researchers found little difference in outcomes. In terms of cost, mindfulness training — often viewed as more costly because it requires more time with a trained therapist — was not significantly more pricey, particularly when given in group sessions, the study found. Richard Byng, a professor at Britain’s Plymouth University Peninsula Schools of Medicine and Dentistry, said that, while current standard treatment for chronic depression is to keep taking anti-depressants, many people don’t want to take them for long periods and others want to avoid side-effects. In this study, 424 adults with recurrent major depression who were on maintenance anti-depressant drugs were randomly assigned either to come off their anti-depressants slowly and receive MBCT or to stay on their medication. While 212 patients continued taking their anti-depressants, the other 212 attended eight group mindfulness therapy sessions and were given daily home practice as well as an option to have four follow-up sessions over a 12-month period. Study results published in The Lancet medical journal showed that after two years, relapse rates were similar in both groups — at 44 percent in the therapy group versus 47 percent in the anti-depressant drug group. “Whilst this study doesn’t show that mindfulness-based cognitive therapy works any better than maintenance anti-depressant medication in reducing the rate of relapse ... these results suggest a new choice for the millions of people with recurrent depression on repeat prescriptions,” said Willem Kuyken of Oxford University, who worked with Byng on the research. Claim: Mindfulness therapy as good as medication for chronic depression - study.
[EX A]: Mindfulness-based cognitive therapy (MBCT) may be just as effective as anti-depressants in helping prevent people with chronic depression from relapsing, scientists said on Tuesday.

[EX Q]: Paragraph: Shares of the company traded marginally down at $132.47, after having closed up 1.7% on Monday. (bit.ly/2ZkZGze)    J&J said that the FTC had issued a “civil investigative demand,” or CID, the equivalent of a subpoena to determine if the contracting practices were legal. Pfizer Inc filed a lawsuit against J&J in 2017, saying its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and aimed at blocking sales of Pfizer’s biosimilar called Inflectra. Pfizer said in the lawsuit that J&J had contracted with many insurers to give discounts in exchange for giving preference to Remicade, and to only pay for Inflectra in cases where Remicade proved to be ineffective. Inflectra was approved in 2016 while Remicade went on the market in 1998. Remicade is an infused treatment for chronic autoimmune disorders and costs about $4,000 per dose, or $26,000 a year, Pfizer said in the lawsuit. J&J has denied any wrongdoing and is fighting the Pfizer lawsuit. Pfizer said in a statement that it had received a CID in June. “As Pfizer’s complaint alleges, J&J’s unlawful conduct is designed to prevent Inflectra from being able to compete on its primary point of differentiation – price. Today, Inflectra has an average selling price (ASP) that is more than 22% lower than Remicade,” the company said in a statement. “Despite these facts, J&J has not lost substantial volume or share of sales – counter to what should occur in a competitive market.”  Biosimilars are intended to be lower-cost alternatives to expensive biotech medicines. But since they are made from living cells and it is not possible to make an exact copy of the branded medicine, they are not automatically substituted for the existing branded drug the way a generic drug would be. The drugs treat ailments like rheumatoid arthritis, Crohn’s disease and ulcerative colitis. Claim: J&J says FTC probing efforts to protect arthritis drug Remicade.
[EX A]: The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.

[EX Q]: Paragraph: The Southwest Utah Public Health Department said in a Tuesday news release that most of the cases have occurred in residential neighborhoods. Individuals exposed to the deadly virus have been given preventative vaccinations. Rabies can spread to people from the saliva of infected animals including bats, foxes, raccoons and skunks. Officials said most of the rabies cases in southwest Utah occur in bats or animals bitten by bats. Claim: Rabies-carrying bats raising alarm in southwest Utah.
[EX A]:
Health officials are raising alarm after receiving several reports of people interacting with rabies-carrying bats in southwest Utah.